Yosuke Minoda
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (11)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Gastric subepithelial lesions (SELs) < 20 mm are frequently identified during routine endoscopy and account for approximately 90% of all SELs. Although most are benign, a substantial proportion represents gastrointestinal stromal tumors (GISTs), which carry malignant potential even at this small size. Histological confirmation is critical for appropriate risk assessment and treatment planning. However, the diagnostic yield of endoscopic ultrasound‐guided tissue acquisition (EUS‐TA) is limited for SELs < 20 mm due to technical challenges such as lesion mobility and short needle stroke. Mucosal incision–assisted biopsy (MIAB), which enables direct visualization and targeted sampling, has emerged as a practical alternative. This narrative review summarizes current evidence on endoscopic diagnostic approaches for SELs < 20 mm, including both sampling methods (EUS‐TA, MIAB) and nonsampling techniques such as contrast‐enhanced EUS, elastography, and artificial intelligence (AI)‐assisted image analysis. Each modality has distinct advantages and limitations, and selection should be based on lesion characteristics, endoscopist experience, and resource availability. Nonsampling modalities offer complementary information and are expected to become increasingly relevant. A comprehensive understanding of available diagnostic techniques is essential to support accurate clinical decision‐making for SELs < 20 mm.
Year:
2026
Objectives To compare the efficacy and safety of sedation with midazolam and remimazolam for colorectal endoscopy. Methods This single‐center, two‐arm, post‐hoc analysis of the REM‐IICTJP01 study investigated the efficacy and safety of remimazolam for gastrointestinal endoscopic sedation. We enrolled 40 and 208 patients who underwent colonoscopy under remimazolam and midazolam sedation, respectively, during the same period. The primary outcome was the time from the end of the colonoscopy until discharge. The secondary outcomes included the time from the end of the colonoscopy until awakening, dosage, and adverse events. Propensity score matching was employed to eliminate the effect of confounding factors. Results Thirty‐seven patients in each group were matched. After propensity matching, the time to awakening after colonoscopy was 28.0 (13.0–37.0) min in the midazolam group and 0 (0–0) min in the remimazolam group; moreover, the time till discharge was 40.0 (35.0–46.5) min in the midazolam group and 0 (0–5.0) min in the remimazolam group, both of which were significantly shorter in the remimazolam group ( p < 0.01). The number of additional doses was 0 (0–0) and 2 (1–3) in the midazolam and remimazolam groups, respectively. The total dose was 2.0 (2.0–3.5) and 6.0 (5.0–7.0) mg in the midazolam and remimazolam groups, respectively. Conclusions Remimazolam yielded significantly faster times to awakening and discharge safely compared to midazolam.
Year:
2025
Objectives In gastroenterology, sedation demand is increasing, although elderly patients are more prone to experiencing adverse events. Remimazolam, a novel ultra‐short‐acting benzodiazepine, may reduce recovery time after endoscopic procedures. Methods This study was a secondary analysis of the investigator‐initiated trial, which investigated the efficacy and safety of remimazolam in gastrointestinal endoscopy (REM‐IICT JP01). Remimazolam sedation was administered during upper gastrointestinal endoscopy. Patients were divided into two groups: 45 non‐elderly and 11 elderly patients (aged ≥65 years). The primary outcome was sedation success. Secondary outcomes included the dose required for sedation, time to awakening, time to regain the ability to walk, and occurrence of adverse events. Results Endoscopic sedation was successful in 95.6% of the non‐elderly group and 100% of the elderly group. The total dose of remimazolam was significantly higher in the non‐elderly group (4.0 [3.0–8.0] mg) than in the elderly group (3.0 [2.0–3.0] mg; p < 0.01). The time to awakening was 0.0 (0.0–10.0) min in the non‐elderly group compared to 0.0 (0.0–30.0) min ( p = 0.98) in the elderly group. The time to regain the ability to walk was significantly longer in the elderly group (5.0 [0.0–60.0] min) than in the non‐elderly group (5.0 [0.0–30.0] min; p = 0.03). During the procedure, adverse events included hypotension in two cases (4.4%) in the non‐elderly group and hypoxemia in one case (9.0%) in the elderly group. Conclusions Upper gastrointestinal endoscopy with remimazolam was effective and safe, regardless of age.
Year:
2025
Aim This study aimed to compare the use of remimazolam and midazolam in upper gastrointestinal endoscopy in Japan as a sub‐analysis of data from an investigator‐initiated clinical trial of remimazolam. Methods and Results Patients in two groups were matched using propensity score matching. We evaluated the time from the end of the gastrointestinal endoscopy until discharge, the time from the end of the procedure until awakening, and adverse events. Overall, 36 participants from the clinical trial population who underwent upper gastrointestinal endoscopy using remimazolam and 199 patients who underwent the procedure with midazolam during the same period were included in this study. Following propensity score matching, 34 patients in both groups were matched. The median time from the end of the procedure until awakening was 27.0 min (23.0–40.5 min) in the midazolam group (Group M) and 0 min (0–5.0 min) in the remimazolam group (Group R); the median time from the end of the upper gastrointestinal endoscopy until discharge was 39.0 min (35.0–52.5 min) in Group M and 5.0 min (0–5.0 min) in Group R ( p < 0.01). Reported adverse events were hypotension and hypoxemia in one patient in Group R. Conclusion Compared with midazolam, remimazolam significantly shortened the time to patient awakening and duration until the patient could leave the endoscopy room. Trial Registration: The main study (REM‐IICT JP1) is registered with the Japan Registry of Clinical Trails: jRCT2031200360
Year:
2025
Objectives Endoscopic ultrasound‐guided fine‐needle aspiration/biopsy (EUS‐FNA/B) is the gold standard for diagnosing gastric subepithelial lesions (SELs), but diagnosing lesions smaller than 20 mm remains challenging. We developed traction‐assisted EUS‐FNB (TA‐EUS‐FNB) using the clip‐with‐thread method to enhance diagnostic accuracy by stabilizing the lesion and providing counter‐traction for easier needle access. This study evaluates the effectiveness of TA‐EUS‐FNB in diagnosing small gastric SELs. Methods In this prospective, randomized, controlled cross‐over trial (August 2019–November 2022), 30 patients with gastric SELs <20 mm were randomized to undergo TA‐EUS‐FNB or conventional EUS‐FNB. Each patient underwent four punctures, two per method. The primary end‐point was the adequate tissue sampling rate for both techniques. Secondary end‐points included diagnostic yield and performance (sensitivity and specificity) in distinguishing gastrointestinal stromal tumors (GISTs) from non‐GISTs. Results The mean tumor size was 15.0 mm, with diagnoses comprising GISTs ( n = 15, 50%), leiomyomas ( n = 8, 26.7%), schwannomas ( n = 2, 6.7%), aberrant pancreas ( n = 3, 10%), and inflammation ( n = 2, 6.7%). TA‐EUS‐FNB demonstrated a significantly higher adequate‐tissue sampling rate (90% vs. 66.7%, P = 0.035) and diagnostic yield (86.7% vs. 63.3%, P = 0.037) than conventional EUS‐FNB. Sensitivity (86.7%, 95% confidence interval [CI] 62.1–96.3% vs. 66.7%, 95% CI 41.7–84.8%; P = 0.20) and specificity (100%, 95% CI 79.6–100% vs. 100%, 95% CI 79.6–100%) were comparable between the methods. No adverse events were observed in the study. Conclusion TA‐EUS‐FNB demonstrated superior tissue sampling rates and diagnostic yield for SELs <20 mm compared to conventional EUS‐FNB, making it a viable option. Controlling lesion mobility is essential for successful EUS‐FNB in small SELs.
Year:
2025
Objectives Most esophageal cancers in Japan are squamous cell carcinomas; however, there has been some concern regarding a recent increase in Barrett's esophageal adenocarcinoma (BEA). This study aimed to clarify the clinical characteristics and outcomes of patients treated via endoscopic submucosal dissection (ESD) in Kyushu, including changes over time. Methods This multicenter, retrospective, observational study was conducted among 21 institutes situated in Kyushu. Data from patients who underwent ESD for BEA or esophageal squamous cell carcinoma between January 2010 and December 2023 were extracted from the pathology database and reviewed. Results The total number of esophageal ESD cases increased from 2299 over the first 7 years to 4009 over the second seven. The incidence of BEA increased from 3.6% (86/2299) over the earlier period to 4.7% (197/4009; p = 0.034) over the latter. We analyzed data from 283 patients (287 lesions). Smaller tumor‐sized lesions were detected over the latter period (14.2 ± 11.6 vs. 11.2 ± 9.5 cm 2 , p = 0.022), significantly reducing treatment times (122.1 ± 81.2 vs. 93.2 ± 53.3 min p < 0.001). The procedure was safe, with low incidence rates, over both the earlier and later periods (respectively), of perforation (0% vs. 1.0%), delayed bleeding (1.2% vs. 2.0%), and pneumonia (4.7% vs. 4.6%). Conclusion The proportion of esophageal ESD procedures to treat BEA has increased in Japan's Kyushu region. This procedure has a comparable safety profile to similar ESD procedures used to treat other conditions.
Year:
2025
Year:
2023
Collaborators (3)
Yoshihiro Ogawa
Distinguished Professor
Kyushu University
Daisuke Yamaguchi
Saga University
YOSHITAKA HATA
Project assistant professor
Kyushu University
Make your next move.
Prepare your application
Review drafts before you send them.